以5-HT_(1A)受体为靶标的抗抑郁药物研究进展  

Progress of antidepressant drugs based on 5-HT_(1A) receptor as a new target

作　　者：陈红霞[1] 张黎明[1] 薛瑞[1] 李云峰[1] 

机构地区：[1]军事医学科学院毒物药物研究所,全军军事认知与心理卫生研究中心,北京100850

出　　处：《军事医学》2013年第8期624-627,共4页Military Medical Sciences

基　　金：国家自然科学基金资助项目(81102423;81001653;81173036)

摘　　要：5-HT1A受体是含量最丰富的5-HT受体亚型,广泛分布于脑内,与抑郁症关系密切。抑郁症患者的5-HT1A受体表达异常,改变5-HT1A受体表达则影响抗抑郁治疗的效果;联合应用5-HT1A受体激动剂与选择性5-HT重摄取抑制剂(SSRIs)能够增强SSRIs的抗抑郁作用,缩短起效时间。近年研究发现,5-HT1A受体转录调控区C(-1019)G基因多态性与抑郁症的发病相关,并影响抗抑郁药物的效应。该文综述了5-HT1A受体在抑郁症发生和治疗中的作用及其作为药物研发新靶点的研究进展。The serotonin-1A（5-HT1A） receptor is among the most abundant and widely distributed 5-HT receptors in the brain.It is reported that 5-HT1A receptor is closely related to depression.Alteration in 5-HT1A receptor levels is commonly observed in depressed individuals,and alteration of 5-HT1A receptor expression with change the antidepressant response.Several 5-HT1A receptor agonists,including pindolol and buspirone,have been used in augmentation with selective serotonin reuptake inhibitors（SSRIs） to accelerate or enhance their antidepressant action.The C（-1019） G 5-HT1A promoter gene polymorphism is associated with depression and is critical to antidepressant action.This paper reviews the relationship between 5-HT1A receptor,depression and antidepressant treatments.The potential of 5-HT1A receptor as targets for new antidepressant compounds for treatment-resistant depression is also highlighted.

关 键 词：抑郁症 5-HT1A受体 抗抑郁药 基因多态性 新靶标 

分 类 号：R749.41[医药卫生—神经病学与精神病学] R964[医药卫生—临床医学]